- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01037985
Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty
July 9, 2021 updated by: Pfizer
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, WITHIN-SUBJECT CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY OF EXC 001 FOR THE AMELIORATION OF SCARRING OF THE SURGICAL INCISION IN SUBJECTS UNDERGOING AN ELECTIVE ABDOMINOPLASTY
This study will compare how well EXC 001 works versus placebo in reducing the appearance of scars in subjects undergoing elective abdominoplasty.
The study will also evaluate the safety of EXC 001 in healthy adult subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
41
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
La Jolla, California, United States, 92037
- Scripps medical
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University,Division of Plastic Surgery
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Barnes Jewish West County Hospital
-
Saint Louis, Missouri, United States, 63141
- Body Aesthetic Plastic Surgery
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Jewell Plastic Surgery Center
-
Tualatin, Oregon, United States, 97062
- Connall Consmetic Surgery
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must have sufficient excess abdominal tissue to qualify for a standard elective abdominoplasty
- Subject has chosen to have an elective abdominoplasty
- Medically healthy with normal screening results
- Subjects must not be pregnant or lactating
Exclusion Criteria:
- Females who are currently pregnant or pregnant during the 12 months prior to inclusion in the study, or lactating
- Participation in another clinical trial within 30 days prior to the start of the study
- Any other condition or prior therapy, which, in the opinion of the PI, would make the subject unsuitable for this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
Multiple intradermal injections of EXC 001 and placebo
|
EXPERIMENTAL: EXC 001
|
Multiple intradermal injections of EXC 001 and placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expert Panel Scar Assessment Score at Week 12: Part B
Time Frame: Week 12
|
Scar assessment by an expert panel was done on blinded photographs using 100 millimeter (mm) visual analog scale (VAS) where a score of 0 = best possible scar and a score of 100 = worst possible scar.
A pair of photographs for each participant were presented and evaluated 3 times by an expert panel.
|
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Expert Panel Scar Assessment Score at Week 24: Part B
Time Frame: Week 24
|
Scar assessment by an expert panel was done on blinded photographs using 100 mm VAS where a score of 0 = best possible scar and a score of 100 = worst possible scar.
A pair of photographs for each participant was presented and evaluated 3 times by an expert panel.
|
Week 24
|
Physician Observer Scar Assessment Score at Week 12 and 24: Part B
Time Frame: Week 12 and 24
|
Physician assessment of scar was done using a valid published 10-point rating scale.
Physician rated vascularity, pigmentation, thickness, relief, pliability, surface area and overall opinion for a scar on a score of 1 = normal skin to 10 = worst scar imaginable.
Composite score was the sum of all the scores except the overall opinion score and range from 6 (best score) to 60 (worst score).
|
Week 12 and 24
|
Participants Observer Scar Assessment Score at Week 12 and 24: Part B
Time Frame: Week 12 and 24
|
Participants rated pain, itching, color, stiffness, thickness, irregularity, and overall opinion of scar on 10-point scale.
For pain and itching associated with scar: range = 1 (no, not at all) to 10 (yes, worst imaginable) and for other parameters associated with scar compared to normal skin: range = 1 (no, same as normal skin) to 10 (yes, very different).
Composite score = sum of all scores except overall opinion, range 6 (best) to 60 (worst).
Scar appearance composite score = sum of all scores except overall opinion, pain and itching, range 4 (best) to 40 (worst).
|
Week 12 and 24
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 of Part A up to Week 24 of Part B
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
AEs included SAEs and all non-SAEs that occurred during the study.
|
Day 1 of Part A up to Week 24 of Part B
|
Number of Participants With Abnormal Physical Examinations Findings: Part A and Part B
Time Frame: Day 1 of Part A up to Week 12 of Part B
|
Physical examination included the assessment of skin; head, ears, eyes, nose, and throat; respiratory; cardiovascular; abdomen; musculoskeletal; neurological; gastrointestinal; genitourinary; endocrine and lymph nodes.
Abnormal physical examinations findings was based on investigator's discretion.
|
Day 1 of Part A up to Week 12 of Part B
|
Number of Participants With Clinically Significant Findings in Electrocardiogram (ECG): Part A and Part B
Time Frame: Day 1 of Part A up to Week 12 of Part B
|
Number of participants with clinically significant abnormality in ECG were reported.
Clinical significance was based on investigator's discretion.
|
Day 1 of Part A up to Week 12 of Part B
|
Number of Participants With Clinically Significant Findings in Laboratory Examinations: Part A and Part B
Time Frame: Day 1 of Part A up to Week 12 of Part B
|
Laboratory analysis included hematology, biochemistry and urinalysis.
Hematology range: basophils (bas) 0-0.2, eosinophils (eos) 0-0.4,
leukocytes (leu) 4-10.5, lymphocytes (lym) 0.7-4.5, neutrophils (neu) 1.8-7.8,
platelet 140-415, monocytes (mon) 0.1-1 in 10^9 per liter; bas/leu 0-3, eos/leu 0-7, lym/leu 14-46, mon/leu 4-13, neu/leu and neu/leu 40-74 in percentage, erythrocytes 3.8-5.1 10^12/L, hematocrit 0.34-0.44
L/L, hemoglobin 115-150 gram per liter (g/L).
Biochemistry range: creatine kinase 24-173, alkaline phosphatase 25-150, alanine aminotransferase (AT) and aspartate AT 0-40 in International units per liter; creatinine 50-88, urate 89-399, bilirubin 2-21 in micromole per liter, glucose 3.6-5.5,
potassium 3.5-5.5,
sodium 135-148, blood urea nitrogen 1.8-9.3 in millimole/L, albumin 35-55 g/L.
Urinalysis parameters: pH (5-7.5),
specific gravity (1.005-1.03).
Participants with clinically significant findings were reported.
|
Day 1 of Part A up to Week 12 of Part B
|
Number of Participants With Clinically Significant Findings in Vital Signs and Weight: Part A and Part B
Time Frame: Day 1 of Part A up to Week 12 of Part B
|
Following vital sign parameters were assessed: diastolic blood pressure, systolic blood pressure, respiration rate, pulse rate, and temperature.
Number of participants with clinically significant change in any vital sign parameter and weight compared to baseline were reported.
Clinical significance was based on investigator's discretion.
|
Day 1 of Part A up to Week 12 of Part B
|
Number of Participants With Positive Skin Sensitivity Reaction: Part A and Part B
Time Frame: Day 21 of Part A up to Day 14 of Part B
|
Participants were instructed to inform the investigator in case of any itching, redness, pain or any other symptom that appears to be a rash at the injection sites.
Erythematous, raised (indurated) and edematous reactions were considered as positive skin sensitivity reactions.
|
Day 21 of Part A up to Day 14 of Part B
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 3, 2009
Primary Completion (ACTUAL)
July 7, 2010
Study Completion (ACTUAL)
September 22, 2010
Study Registration Dates
First Submitted
December 21, 2009
First Submitted That Met QC Criteria
December 22, 2009
First Posted (ESTIMATE)
December 23, 2009
Study Record Updates
Last Update Posted (ACTUAL)
August 2, 2021
Last Update Submitted That Met QC Criteria
July 9, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- EXC 001-202
- B5301010 (OTHER: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scar Prevention
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Lumenis Be Ltd.Terminated
-
PfizerCompletedScar PreventionUnited States
-
Thammasat University HospitalActive, not recruiting
-
PfizerCompleted
-
Lemonex Inc.CompletedCicatrix | Scar PreventionKorea, Republic of
-
RXi Pharmaceuticals, Corp.CompletedCicatrix | Scar PreventionUnited States
-
RXi Pharmaceuticals, Corp.Completed
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Hallym University Kangnam Sacred Heart HospitalRecruitingIntense Pulsed Light | Erbium-yttrium Aluminum Garnet Laser | Scar PreventionKorea, Republic of
Clinical Trials on EXC 001
-
PfizerCompletedScar PreventionUnited States
-
PfizerCompletedReduction in Hypertrophic Skin ScarringUnited States
-
PfizerCompleted
-
PfizerCompletedReduction in Severity of Skin ScarringUnited States
-
Columbia UniversityNot yet recruitingObsessive-Compulsive Disorder | Anxiety DisordersUnited States
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
JANSSEN Alzheimer Immunotherapy Research & Development...TerminatedAlzheimer's DiseaseUnited States
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina